$11.39
0.97%
Downside
Day's Volatility :4.57%
Upside
3.64%
17.3%
Downside
52 Weeks Volatility :46.11%
Upside
34.84%
Period | Dynavax Technologies Corporation | |
---|---|---|
3 Months | 17.32% | |
6 Months | 1.74% | |
1 Year | -0.39% | |
3 Years | 40.75% |
Market Capitalization | 1.5B |
Book Value | $4.39 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | 1.57 |
PE Ratio | 7.25 |
PEG Ratio | 0.0 |
Wall Street Target Price | 22.8 |
Profit Margin | 35.99% |
Operating Margin TTM | 40.19% |
Return On Assets TTM | 16.64% |
Return On Equity TTM | 55.44% |
Revenue TTM | 655.6M |
Revenue Per Share TTM | 5.15 |
Quarterly Revenue Growth YOY | -58.8% |
Gross Profit TTM | 448.2M |
EBITDA | 267.3M |
Diluted Eps TTM | 1.57 |
Quarterly Earnings Growth YOY | -0.31 |
EPS Estimate Current Year | -0.53 |
EPS Estimate Next Year | -0.25 |
EPS Estimate Current Quarter | -0.13 |
EPS Estimate Next Quarter | -0.12 |
What analysts predicted
Upside of 100.18%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 327.0K | ↓ 97.04% |
Net Income | -95.2M | ↓ 15.38% |
Net Profit Margin | -29.1K% | ↓ 28080.84% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 8.2M | ↑ 2407.03% |
Net Income | -158.9M | ↑ 66.99% |
Net Profit Margin | -1.9K% | ↑ 27160.81% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 35.2M | ↑ 329.6% |
Net Income | -152.6M | ↓ 3.96% |
Net Profit Margin | -433.29% | ↑ 1504.98% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 46.6M | ↑ 32.18% |
Net Income | -75.2M | ↓ 50.69% |
Net Profit Margin | -161.63% | ↑ 271.66% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 439.4M | ↑ 844.0% |
Net Income | 76.7M | ↓ 201.96% |
Net Profit Margin | 17.46% | ↑ 179.09% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 722.7M | ↑ 64.45% |
Net Income | 293.2M | ↑ 282.15% |
Net Profit Margin | 40.56% | ↑ 23.1% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 195.1M | ↑ 80.17% |
Net Income | 99.8M | ↓ 450.96% |
Net Profit Margin | 51.15% | ↑ 77.41% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 114.0M | ↓ 41.56% |
Net Income | 32.9M | ↓ 67.07% |
Net Profit Margin | 28.83% | ↓ 22.32% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 256.5M | ↑ 124.98% |
Net Income | 128.8M | ↑ 291.84% |
Net Profit Margin | 50.2% | ↑ 21.37% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 167.7M | ↓ 34.6% |
Net Income | 63.8M | ↓ 50.44% |
Net Profit Margin | 38.04% | ↓ 12.16% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 184.5M | ↑ 9.99% |
Net Income | 67.7M | ↑ 6.15% |
Net Profit Margin | 36.71% | ↓ 1.33% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 46.9M | ↓ 74.57% |
Net Income | -24.3M | ↓ 135.92% |
Net Profit Margin | -51.85% | ↓ 88.56% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 218.8M | ↑ 99.48% |
Total Liabilities | 19.2M | ↓ 6.07% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 210.9M | ↓ 3.61% |
Total Liabilities | 147.8M | ↑ 668.45% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 279.1M | ↑ 32.33% |
Total Liabilities | 270.8M | ↑ 83.18% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 353.3M | ↑ 26.59% |
Total Liabilities | 294.6M | ↑ 8.79% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | ↑ 194.18% |
Total Liabilities | 816.9M | ↑ 177.3% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 985.9M | ↓ 5.14% |
Total Liabilities | 404.8M | ↓ 50.44% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 1.0B | ↑ 13.0% |
Total Liabilities | 816.9M | ↓ 4.14% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.0B | ↓ 2.91% |
Total Liabilities | 721.5M | ↓ 11.68% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.0B | ↑ 1.39% |
Total Liabilities | 600.2M | ↓ 16.81% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 999.3M | ↓ 2.31% |
Total Liabilities | 498.8M | ↓ 16.9% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 985.9M | ↓ 1.35% |
Total Liabilities | 404.8M | ↓ 18.83% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 969.9M | ↓ 1.62% |
Total Liabilities | 406.2M | ↑ 0.33% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -77.5M | ↓ 27.59% |
Investing Cash Flow | -108.7M | ↓ 226.03% |
Financing Cash Flow | 187.8M | ↑ 35275.14% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -131.3M | ↑ 69.38% |
Investing Cash Flow | 55.5M | ↓ 151.03% |
Financing Cash Flow | 99.1M | ↓ 47.26% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -121.3M | ↓ 7.65% |
Investing Cash Flow | -42.8M | ↓ 177.13% |
Financing Cash Flow | 154.4M | ↑ 55.8% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -92.3M | ↓ 23.92% |
Investing Cash Flow | -26.5M | ↓ 37.98% |
Financing Cash Flow | 109.5M | ↓ 29.06% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 335.5M | ↓ 463.71% |
Investing Cash Flow | 14.2M | ↓ 153.61% |
Financing Cash Flow | 55.8M | ↓ 49.06% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 120.5M | ↑ 81.99% |
Investing Cash Flow | 54.9M | ↑ 20.29% |
Financing Cash Flow | 14.8M | ↑ 178.39% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -50.4M | ↓ 141.86% |
Investing Cash Flow | -216.5M | ↓ 494.05% |
Financing Cash Flow | 10.3M | ↓ 30.57% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 16.7M | ↓ 133.01% |
Investing Cash Flow | 52.5M | ↓ 124.25% |
Financing Cash Flow | 1.0M | ↓ 90.01% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 61.6M | ↑ 269.71% |
Investing Cash Flow | -119.0M | ↓ 326.75% |
Financing Cash Flow | 8.1M | ↑ 683.75% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 27.6M | ↓ 20.96% |
Investing Cash Flow | -52.3M | - |
Financing Cash Flow | -3.1M | ↓ 2119.61% |
Sell
Neutral
Buy
Dynavax Technologies Corporation is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Dynavax Technologies Corporation | 4.34% | 1.74% | -0.39% | 40.75% | 40.75% |
![]() Neurocrine Biosciences Inc. | -3.43% | -21.81% | -0.94% | -21.05% | -5.78% |
![]() Haleon Plc Spon Ads | -7.07% | 4.76% | 9.99% | 9.99% | 9.99% |
![]() Zoetis Inc. | -11.91% | 6.69% | 0.99% | 16.57% | 87.33% |
![]() Viatris Inc. | -2.11% | -15.73% | -16.18% | -42.55% | -42.55% |
![]() Catalent, Inc. | 15.54% | -14.7% | -63.62% | -48.0% | -2.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Dynavax Technologies Corporation | 7.25 | 7.25 | 0.0 | -0.53 | 0.55 | 0.17 | 0.0 | 4.39 |
![]() Neurocrine Biosciences Inc. | 151.66 | 151.66 | 1.87 | 1.93 | 0.04 | 0.08 | 0.0 | 17.28 |
![]() Haleon Plc Spon Ads | 27.5 | 27.5 | NA | 0.0 | 0.05 | 0.04 | 0.01 | 3.54 |
![]() Zoetis Inc. | 35.69 | 35.69 | 3.53 | 5.4 | 45.26 | 0.13 | 0.01 | 9.72 |
![]() Viatris Inc. | 6.01 | 6.01 | NA | 2.95 | 0.09 | 0.03 | 0.05 | 17.45 |
![]() Catalent, Inc. | 16.84 | 16.84 | 1.18 | 1.37 | 0.09 | 0.04 | 0.0 | 27.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Dynavax Technologies Corporation | Buy | $1.5B | 40.75% | 7.25 | 35.99% |
![]() Neurocrine Biosciences Inc. | Buy | $9.2B | -5.78% | 151.66 | 4.0% |
![]() Haleon Plc Spon Ads | Buy | $38.2B | 9.99% | 27.5 | 9.86% |
![]() Zoetis Inc. | Buy | $75.6B | 87.33% | 35.69 | 25.59% |
![]() Viatris Inc. | Hold | $11.3B | -42.55% | 6.01 | 12.05% |
![]() Catalent, Inc. | Buy | $7.1B | -2.17% | 16.84 | 8.62% |
BlackRock Inc
Federated Hermes Inc
State Street Corporation
Vanguard Group Inc
Deep Track Capital, LP
Chicago Capital, LLC
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Organization | Dynavax Technologies Corporation |
Employees | 351 |
CEO | Mr. Ryan Spencer |
Industry | Health Technology |
Smart For Life Inc
$1.14
-2.56%
Paysign, Inc.
$2.64
+2.33%
Novavax, Inc.
$7.47
-2.86%
Silvercrest Metals Inc
$6.27
-2.18%
Fidelity U.s. Multifactor Etf
$25.43
-0.04%
Proshares Ultrapro Dow30 Etf
$57.69
+0.47%
Invesco Dynamic Large Cap Va
$45.62
-0.02%
Blackrock Municipal Income Quality Trust
$11.15
+0.18%
Tupperware Brands Corporation
$0.86
+0.83%